Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Allurion Technologies Inc Market Cap
The Allurion Technologies Inc (ALUR) share price is expected to increase by 409.26% over the next year. This is based on calculating the average 12-month share price estimate provided by 4 stock analysts who have covered ALUR. Price targets range from $1.5 at the low end to $2 at the high end. The current analyst consensus for ALUR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assignedALUR 3 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Allurion Technologies Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ALUR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ALUR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Keay Nakae Chardan Capital | Neutral | Downgrade | Nov 14, 2024 | |
| Joshua Jennings TD Cowen | Buy | $2 | Initiates | Oct 2, 2024 |
| Jason Wittes Roth MKM | Buy | $2 | Initiates | Sep 6, 2024 |
| Keay Nakae Chardan Capital | Buy | $2.5 | Maintains | Aug 22, 2024 |
| Keay Nakae Chardan Capital | Buy | $5 | Maintains | May 15, 2024 |
| Keay Nakae Chardan Capital | Buy | $5 | Initiates | Apr 4, 2024 |
| Matthew Taylor Jefferies | Buy | $5 | Initiates | Feb 9, 2024 |
When did it IPO
2023
Staff Count
501
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. Shantanu K. Gaur M.D.
Market Cap
$27.5M
In 2023, ALUR generated $53.5M in revenue, which was a decrease of -16.73% from the previous year. This can be seen as a signal that ALUR's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Allurion Technologies, Inc. (NYSE: ALUR) has received NYSE approval for its plan to regain compliance with the Minimum Market Capitalization Standard, ensuring its continued listing.
Why It Matters - Allurion Technologies' acceptance letter from the NYSE indicates progress in meeting listing standards, potentially stabilizing its stock price and restoring investor confidence.
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Allurion Technologies (NYSE: ALUR) launched AllurionMeds, integrating affordable weight loss medications with an AI platform for weight maintenance and virtual dietician access.
Why It Matters - Allurion's launch of AllurionMeds signals innovation in obesity treatment, potentially boosting patient engagement and revenue growth, impacting stock performance positively.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Allurion Technologies Inc. (NYSE:ALUR) will hold its Q3 2024 earnings conference call on November 13, 2024, at 8:30 AM ET, featuring key company executives and analysts.
Why It Matters - The upcoming Q3 2024 earnings call for Allurion Technologies will provide insights into financial performance and strategic direction, influencing investor sentiment and stock valuation.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Allurion Technologies reported Q3 2024 revenue of $5.4 million, impacted by a $1.2 million product recall in France. AI product revenue from the Virtual Care Suite increased by 82%.
Why It Matters - Allurion's Q3 revenue of $5.4 million, affected by a product recall, highlights operational challenges. However, the 82% growth in AI product revenue indicates potential for future recovery and growth.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Allurion Technologies, Inc. (NYSE: ALUR) presented two abstracts at Obesity Week 2024, including data from a large real-world cohort of 19,428 patients treated with the Allurion Program.
Why It Matters - Positive data presentations at a major medical conference can enhance Allurion's credibility, attract investor interest, and potentially drive stock performance due to increased visibility in the obesity treatment market.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Allurion Technologies, Inc. (NYSE: ALUR) will report Q3 2024 financial results on November 13, 2024, followed by a conference call at 8:30 AM ET.
Why It Matters - The upcoming Q3 2024 financial results and conference call will provide insights into Allurion's performance and strategy, crucial for evaluating its growth potential and investment viability.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
